US 12370153

US Patent 12370153, titled "Ready-to-use ketamine premix formulation," was issued on July 29, 2025 [cite: Publication date 2025-07-29]. The patent was filed on July 11, 2024, under application number US18/770,514 [cite: Filing date 2024-07-11]. The inventor is Sergio Dusci, and the current assignee is Inforlife SA [cite: Inventor Sergio Dusci, Current Assignee Inforlife SA].

Abstract:
The invention describes a sterile, ready-to-use, and stable aqueous solution of ketamine designed for direct intravenous infusion. This premixed formulation is contained within a sealed infusion container and is notable for being free of antimicrobials like benzethonium chloride, while maintaining a long shelf-life. It is intended for use in patients requiring anesthesia for diagnostic or surgical procedures.

Plain-Language Overview of Independent Claims:

• Claim 1: This claim covers a ready-to-use, sterile ketamine product. It includes an aqueous ketamine solution with a concentration between approximately 0.5 to 2.5 mg/mL, a tonicity adjusting agent, a pH adjusting agent, and water for injection. A key feature is that the ketamine solution does not contain benzethonium chloride.
• Claim 35: This claim describes a ready-to-use ketamine product that is contained in a terminally sterilized infusion container. The product consists of an aqueous ketamine solution with a concentration of about 0.5 to 2.5 mg/mL, a tonicity adjusting agent, a pH adjusting agent, and water for injection, and is specifically free of preservatives.

Litigation Information:
The patent family has pending litigation, specifically a PTAB (Patent Trial and Appeal Board) case identified as PGR2026-00036 [cite: PTAB case PGR2026-00036 filed (Pending), https://portal.unifiedpatents.com/ptab/case/PGR2026-00036]. No specific dockets for US12370153 in the CAFC (Court of Appeals for the Federal Circuit) 2026 dockets were found in the provided search results.